Download PDF
Pharmacopsychiatry 2015; 48(01): 25-29
DOI: 10.1055/s-0034-1394396
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

The Effectiveness of a Computer Reminder System for Laboratory Monitoring of Metabolic Syndrome in Schizophrenic Outpatients Using Second-generation Antipsychotics

C.-L. Lai
1   Department of General Psychiatry, Taoyuan Psychiatric Center, Taoyuan City, Taiwan
,
H.-Y. Chan
1   Department of General Psychiatry, Taoyuan Psychiatric Center, Taoyuan City, Taiwan
2   Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
,
Y.-J. Pan
3   Department of Psychiatry, Far Eastern Memorial Hospital, Taipei, Taiwan
4   Department of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan
,
C.-H. Chen
1   Department of General Psychiatry, Taoyuan Psychiatric Center, Taoyuan City, Taiwan
› Author Affiliations
Further Information

Publication History

received 02 August 2014
revised 21 September 2014

accepted 29 September 2014

Publication Date:
28 October 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: A computer reminder system (CRS) may help psychiatrists follow guidelines and monitor patients at risk of metabolic syndrome. This study explores the effectiveness of a CRS for outpatients with schizophrenia.

Methods: The study data were collected from July 2004 to July 2008. A CRS was implemented in July 2006. The intervention group was patients taking either clozapine, olanzapine, risperidone, or quetiapine with a CRS. The control group was patients taking either sulpiride or zotepine without a CRS. We defined a qualified patient visit (QPV) as a visit in which metabolic monitoring adhered to established guidelines when the patient visit was within 6 months of performing the recommended laboratory examinations. We compared the percentage difference in QPVs between the 2 study groups.

Results: The percentage of QPVs in the intervention group was significantly higher than the control group (OR=3.51, 95% CI=1.83~6.73, P=0.0002) after adjusting potential confounding factors. The intervention group was divided into a high metabolic risk (clozapine and olanzapine) subgroup and an intermediate metabolic risk (risperidone and quetiapine) subgroup and compared with the control group. The percentage of QPVs in the high risk subgroup was significantly higher than the intermediate risk subgroup (OR=4.27, 95% CI=2.71~6.75, p<0.0001) and control group (OR=6.99, 95% CI=3.48~14.07, p<0.0001).

Discussion: The percentage of QPVs in the intervention group was higher than the control group and the different metabolic risk of SGAs also influenced the performance of laboratory examinations. Further studies are needed to confirm the results of our studies.

Key words

metabolic syndrome - computer reminder system - schizophrenia - antipsychotics
 

  • References

  • 1 Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 (Suppl. 27) 15-26
    PubMedGoogle Scholar
  • 2 Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62 (Suppl. 23) 30-38
    CrossrefPubMedGoogle Scholar
  • 3 Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002; 16: 77-89
    CrossrefPubMedGoogle Scholar
  • 4 Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25-32
    CrossrefPubMedGoogle Scholar
  • 5 Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-euro-american societies. Clin Neuropharmacol 2012; 35: 141-147
    CrossrefPubMedGoogle Scholar
  • 6 Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (Suppl. 01) 7-14
    CrossrefPubMedGoogle Scholar
  • 7 Morrato EH, Cuffel B, Newcomer JW et al. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009; 29: 26-32
    CrossrefPubMedGoogle Scholar
  • 8 Expert G. ‘Schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 2004; 184: 112-114
    CrossrefPubMedGoogle Scholar
  • 9 De Nayer A, De Hert M, Scheen A et al. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 2007; 33: 197-202
    CrossrefPubMedGoogle Scholar
  • 10 Mitchell AJ, Delaffon V, Vancampfort D et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42: 125-147
    CrossrefPubMedGoogle Scholar
  • 11 Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl. 01) 20-27
    Google Scholar
  • 12 Harris MI, Eastman RC, Cowie CC et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408
    CrossrefPubMedGoogle Scholar
  • 13 Ziemer DC, Doyle JP, Barnes CS et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med 2006; 166: 507-513
    CrossrefPubMedGoogle Scholar
  • 14 Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA 2011; 306: 383
    PubMedGoogle Scholar
  • 15 Phillips LS, Branch WT, Cook CB et al. Clinical inertia. Ann Intern Med 2001; 135: 825-834
    CrossrefPubMedGoogle Scholar
  • 16 Martens JD, van der Aa A, Panis B et al. Design and evaluation of a computer reminder system to improve prescribing behaviour of GPs. Stud Health Tech Informat 2006; 124: 617-623
    PubMedGoogle Scholar
  • 17 McDonald CJ, Hui SL, Smith DM et al. Reminders to physicians from an introspective computer medical record. A two-year randomized trial. Ann Intern Med 1984; 100: 130-138
    CrossrefPubMedGoogle Scholar
  • 18 Wilbur L, Huffman G, Lofton S et al. The use of a computer reminder system in an emergency department universal HIV screening program. Ann Emerg Med 2011; 58 (Suppl. 01) 71-73
    CrossrefPubMedGoogle Scholar
  • 19 Nilasena DS, Lincoln MJ. A computer-generated reminder system improves physician compliance with diabetes preventive care guidelines. Proc Annu Symp Comput Appl Med Care 1995; 640-645
    PubMedGoogle Scholar
  • 20 Agostini JV, Zhang Y, Inouye SK. Use of a computer-based reminder to improve sedative-hypnotic prescribing in older hospitalized patients. J Am Geriatr Soc 2007; 55: 43-48
    CrossrefPubMedGoogle Scholar
  • 21 Del Monte MT, Bostwick JR, Bess JD et al. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics. J Clin Pharm Ther 2012; 37: 668-673
    CrossrefPubMedGoogle Scholar
  • 22 Baptista T, Molina MG, Martinez JL et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 1997; 30: 256-262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Baptista T, Alastre T, Contreras Q et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 1997; 30: 250-255
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 01) 1-93
    CrossrefPubMedGoogle Scholar
  • 25 Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 (Suppl. 27) 15-26 discussion 40–41
    PubMedGoogle Scholar
  • 26 Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics?. J Clin Psychopharmacol 1999; 19: 316-321
    CrossrefPubMedGoogle Scholar
  • 27 Wu RR, Zhao JP, Liu ZN et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006; 186: 572-578
    CrossrefPubMedGoogle Scholar
  • 28 Huang MC, Lu ML, Tsai CJ et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009; 120: 274-280
    CrossrefPubMedGoogle Scholar
  • 29 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
    Google Scholar
  • 30 Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 2000; 160: 41-46
    CrossrefPubMedGoogle Scholar
  • 31 Ziemer DC, Doyle JP, Barnes CS et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med 2006; 166: 507-513
    CrossrefPubMedGoogle Scholar
  • 32 Phillips LS, Ziemer DC, Doyle JP et al. An endocrinologist-supported intervention aimed at providers improves diabetes management in a primary care site: improving primary care of African Americans with diabetes (IPCAAD) 7. Diabetes Care 2005; 28: 2352-2360
    CrossrefPubMedGoogle Scholar
  • 33 Perlin JB, Pogach LM. Improving the outcomes of metabolic conditions: managing momentum to overcome clinical inertia. Ann Intern Med 2006; 144: 525-527
    CrossrefPubMedGoogle Scholar